Core Insights - Teleflex Incorporated has launched Barrigel™ rectal spacer in Japan, following regulatory approval and insurance coverage acceptance, marking a significant step in its global expansion strategy [3][5][11] - Barrigel™ is the first and only sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer, designed to reduce radiation exposure to the rectum during prostate cancer treatment [4][9] - In 2022, prostate cancer was the most common cancer among men in Japan, with 104,318 new cases, representing 18% of all cancer diagnoses nationwide [5] Product Details - Barrigel™ rectal spacer has demonstrated a 98% success rate in achieving at least a 25% reduction in radiation to the rectum in a U.S. clinical study, with an average reduction of 85% in rectal V54 Gy radiation [6] - The product is indicated for prostate cancer patients with T1-T3b disease and is cleared for use in the U.S., Australia, Europe, and Japan [11][12] - Barrigel™ is made from biodegradable NASHA, which is biocompatible and fully absorbable, ensuring safety and efficacy in various medical applications [10][12] Market Impact - The launch in Japan is expected to enhance access to Barrigel™ for men undergoing prostate cancer radiation therapy, minimizing rectal side effects [7] - Teleflex aims to establish Barrigel™ as the standard of care for prostate cancer radiation therapy, emphasizing its innovative technology and precision in placement [5][8] - Training for healthcare professionals in Japan has commenced, led by top radiation oncologists, to ensure effective implementation of the product [8]

Core Insights - Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System's advantages over Rezūm and tamsulosin in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes [2][3] Group 1: UroLift™ System Findings - The UroLift™ System demonstrated significantly higher patient satisfaction at two weeks and one month post-treatment compared to Rezūm, with shorter catheterization times and improved symptom relief [5] - At three months, patients treated with the UroLift™ System showed significantly better symptom improvement and sexual function outcomes compared to those on tamsulosin, with 70% of men on medication opting to switch to UroLift™ [5] - Real-world data from the American Urological Association Quality Registry (AQUA) confirmed that BPH drugs provide limited improvement, while the UroLift™ System offers rapid symptom score improvement at three months [5] Group 2: Safety of Stabilized Hyaluronic Acid (sHA) - The study confirmed the safety of stabilized hyaluronic acid as a rectal spacer, showing a low incidence of rectal wall infiltration and no severe complications, reinforcing its use during prostate cancer treatment [4][5] - The sHA rectal spacer allows for individualized spacing and is effective in protecting patients during radiation therapy, with a focus on its reversibility as a clinical advantage [4]